biostudies-literatureNyland SBNCRR NIH HHSNCI NIH HHS581-7https://www.ebi.ac.uk/biostudies/studies/S-EPMC3312981biostudies-literatureUnknown36(5)Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.Leukemia researchSeroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.PMC3312981U54RR019397CA133525R01 CA133525-05CA112112R01 CA098472U54 RR019397R01 CA112112CA 94872U54 RR019397-01R01 CA098472-09R01 CA133525R01 CA112112-04Clemente MJLoughran TPJarbadan NRBaab KTKrissinger DJLiao JNyland SBPaquette RCuthbertson DList AFIrby RBEpling-Burnette PMaciejewski JPSokol LSchaefer EfalseSeroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.2012-01-01T00:00:00Z2012 May2020-10-29T14:20:30Z2019-03-27T00:51:37ZS-EPMC33129812238672910.1016/j.leukres.2012.02.001